- AATec Medical partners with CDMO Northway Biotech to scale manufacturing of ATL-105.
- ATL-105 is an inhaled recombinant protein therapy targeting non-CF bronchiectasis.
AATec Medical GmbH and Northway Biotech have announced a partnership to develop the industrial production process for ATL-105, AATec’s lead inhaled biologic therapy for respiratory diseases. The agreement focuses on manufacturing process and analytical development for ATL-105, which is based on recombinant alpha-1 antitrypsin (AAT) and targets non-cystic fibrosis bronchiectasis (NCFB).
The collaboration will use Northway Biotech’s expertise as a global CDMO to scale ATL-105 using the Pichia pastoris expression system. The partnership aims to establish a scalable, quality-focused manufacturing process to support both clinical development and potential commercial use.
ATL-105 is designed for direct delivery to the lungs and combines anti-protease, anti-inflammatory, and anti-infective effects in one molecule. According to AATec CEO Rüdiger Jankowsky, “With this partnership, we are establishing a robust and scalable production process for ATL-105, laying the foundation for consistent quality for clinical development and commercial use.”
Northway Biotech will support the programme from its facilities in Vilnius, Lithuania. ATL-105’s lead indication is non-CF bronchiectasis, a chronic respiratory condition affecting millions. However, AATec notes that the therapy may also be suitable for other inflammatory or infectious respiratory diseases, including COPD and ARDS.
